905920-49-2

Upstream product

• 1635-61-6 5-chloro-2-nitroaniline 
• 98-80-6 phenylboronic acid 
• 586-78-7 para-nitrophenyl bromide 
• 92-93-3 1-phenyl-4-nitrobenzene 
• 76129-28-7 4-nitrobiphenyl-3-ylamine 

Downstream Products

• 960307-41-9 C₂₇H₂₅N₃O₅ 
• 960307-26-0 C₂₇H₂₅N₃O₃ 

Relevant academic research and scientific papers

INK COMPOSITION FOR ORGANIC LIGHT-EMITTING DEVICE, ORGANIC LIGHT-EMITTING DEVICE INCLUDING FILM FORMED BY USING THE INK COMPOSITION, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE

An ink composition for an organic light-emitting device, the ink composition including a luminescent host material and a solvent, wherein the luminescent host material includes at least one compound represented by Formula (1), and wherein the solvent includes at least one selected from an aromatic ether, an aromatic ester, and an aromatic ketone: wherein, in Formula (1), groups and variables are the same as described in the specification.

COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, COMPOSITION FOR THE PRODUCTION OF ORGANIC ELECTROLUMINESCENT ELEMENT, AND ORGANIC ELECTROLUMINESCENT ELEMENT

PROBLEM TO BE SOLVED: To provide a novel and improved compound that can improve the thermal stability of an organic layer and extend the emission lifetime of an organic electroluminescent element, and an organic electroluminescent element material, a composition for the production of an organic electroluminescent element, and an organic electroluminescent element each of which comprises the compound. SOLUTION: The present invention provides a compound represented by general formula (1). SELECTED DRAWING: Figure 1 COPYRIGHT: (C)2017,JPOandINPIT

CONDENSED CYCLIC COMPOUND, COMPOSITION INCLUDING THE CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE CONDENSED CYCLIC COMPOUND, AND METHOD OF MANUFACTURING THE ORGANIC LIGHT-EMITTING DEVICE

A condensed cyclic compound represented by Formula (1): wherein, in Formula (1), groups and variables are the same as described in the specification.

CONDENSED CYCLIC COMPOUND, AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME

Disclosed are a condensed ring compound and an organic light emitting device comprising the condensed ring compound. The organic light emitting device comprises: a first electrode; a second electrode facing the first electrode; and an organic layer interposed between the first electrode and the second electrode, wherein the organic layer comprises the condensed ring compound.COPYRIGHT KIPO 2015

TARGETING THE ONCOPROTEIN NUCLEOPHOSMIN

(+)-Avrainvillamide, a naturally occurring alkaloid with antiproliferative activity, is shown to bind to the oncoprotein nucleophosmin. Nucleophosmin is known to regulate the tumor suppressor protein p53 and is overexpressed in many different human tumors. The invention provides methods of modulating nucleophosmin and p53 using (+)-avrainvillamide and analogues thereof. These compounds may provide leads for the development of novel anti-cancer therapies that target nucleophosmin.

The natural product avrainvillamide binds to the oncoprotein nucleophosmin

Here we present evidence that (+)-avrainvillamide, a naturally occurring alkaloid with antiproliferative effects, binds to the nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many different human tumors. Among other effects, nucleophosmin is known to regulate the tumor suppressor protein p53. A synthetic biotin-avrainvillamide conjugate, nearly equipotent to the natural product in inhibiting the growth of cultured T-47D cells, was used for affinity-isolation of a protein identified as nucleophosmin by MS sequencing and Western-blotting. Affinity-isolation of nucleophosmin was inhibited in the presence of iodoacetamide (10 mM), free (+)-avrainvillamide (100 μM), and a series of closely related structural analogues of (+)-avrainvillamide, the latter with inhibitory effects that appear to correlate with measured growth-inhibitory potencies. Using fluorescence microscopy, a synthetic dansyl-avrainvillamide conjugate was observed to localize within the nucleoli and the cytosol of treated cancer cells. Site-directed mutagenesis of each of the three cysteine residues of a truncated nucleophosmin coexpressed with native nucleophosmin in COS-7 cells revealed that the mutation cys275 -ala275 effectively and uniquely reduced affinity-isolation of the truncated protein, suggesting that avrainvillamide targets cys275 of nucleophosmin. Finally, we show that treatment of adhered LNCaP or T-47D cells with (+)-avrainvillamide leads to an increase in cellular p53 concentrations, and that siRNA-promoted depletion of nucleophosmin in a population of HeLa S3 cells leads to increased sensitivity of that population toward apoptotic death upon treatment with (+)-avrainvillamide. Although potentially desirable as lead compounds for the development of novel anticancer therapies, nonpeptidic, synthetic small molecules that bind to nucleophosmin have not been described, prior to this report.